NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-29 10:05இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Sagility Q2 FY27 Earnings Call: Q2 Revenue up 22.5% to ₹2,032 Cr, Chirok Health Acquired
Sagility released its Q2 FY27 earnings call transcript, highlighting consolidated Q2 revenue growth of 22.5% YoY to ₹2,032.1 crore ($212.6 million) and adjusted EBITDA margin of 26.3% (₹535.3 crore). The company secured a minimum $10 million ACV payment integrity deal with a Big Ten health plan covering over 10 million members, bringing total deal ACVs won in the quarter to $40.2 million (up 18.2% YoY). Additionally, Sagility announced the acquisition of Chirok Health LLC (with $13 million TTM revenue) to expand its mid-cycle revenue cycle management offerings, and the board approved an interim dividend of ₹0.15 per share.
உச்சம் நம்பிக்கை
என்ன மாறியதுSagility published its detailed Q2 FY27 conference call transcript outlining operational performance, pipeline health, and the closing of the Chirok Health acquisition.
ஏன் இது முக்கியம்Demonstrates sustained revenue growth (>22% YoY) and solid operating leverage (26.3% adjusted EBITDA margin), while expanding capabilities into provider mid-cycle RCM and agentic AI.
📅 குறுகிய காலம்Sentiment will remain supported by steady margins and healthy quarterly execution across healthcare payer and provider pipelines.
📈 நீண்ட காலம்Cross-selling mid-cycle RCM via Chirok Health and agentic AI tools strengthens Sagility's competitive positioning among top US payers and hospital networks.
⚠ அபாய எச்சரிக்கைகள்
High client concentration (top 10 clients drive >90% of revenue)
Integration risks associated with overseas acquisition of Chirok Health
👀 கவனிக்க வேண்டியவை
Track the integration and margin impact of the newly acquired Chirok Health LLC, along with the revenue ramp-up from the newly won $10+ million payment integrity contract.
Sagility Declares ₹0.15/Share Interim Dividend; Fixes Record Date as October 30, 2026
Sagility Limited has announced an interim dividend of ₹0.15 per equity share of face value ₹10 each for FY2026-27. The Board has fixed Friday, October 30, 2026, as the record date to determine eligible shareholders. The dividend payout is scheduled to be completed on or before November 21, 2026. Relative to the current share price of ₹45.4, the dividend represents a modest yield of approximately 0.33%.
உச்சம் நம்பிக்கை
என்ன மாறியதுSagility announced an interim dividend of ₹0.15 per share and finalized the record and payment schedule.
ஏன் இது முக்கியம்Demonstrates regular shareholder return policy, though the payout is modest relative to the company's TTM EPS of ₹2.11.
Interim Dividend per share: Rs. 0.15/-Face Value: Rs. 10/-ரெக்கார்ட் தேதி: அக்டோபர் 30, 2026Payment Completion Date: on or before November 21, 2026Dividend to CMP yield: ~0.33%
📅 குறுகிய காலம்Ex-dividend price adjustment of ₹0.15 is expected around late October 2026.
📈 நீண்ட காலம்Limited; reflects routine capital allocation and cash distribution.
👀 கவனிக்க வேண்டியவை
Investors seeking dividend eligibility must hold shares before the ex-dividend date associated with the October 30, 2026 record date. Watch for subsequent Q2 FY27 earnings disclosures.
Sagility Q2 FY27 Revenue Up 22.5% YoY to ₹2,032 Cr; Declares ₹0.15 Interim Dividend
Sagility reported consolidated revenue of ₹2,032.1 crore for Q2 FY27, marking a 22.5% YoY increase (12.2% in constant currency). Reported PAT rose 13.3% YoY to ₹284.2 crore, while Adjusted PAT came in at ₹325.4 crore with an Adjusted EBITDA margin of 26.3%. The company secured $40.2 million in annual contract value (ACV) and declared an interim dividend of ₹0.15 per share. Total headcount expanded 16.5% YoY to 51,486, supported by the integration of CareSeed and the acquisition of Chirok Health.
உச்சம் நம்பிக்கை
என்ன மாறியதுSagility delivered solid Q2 FY27 operational earnings, announced an interim dividend of ₹0.15 per share, and acquired Chirok Health LLC to expand into provider revenue cycle management (RCM).
ஏன் இது முக்கியம்The steady performance sustains >20% revenue expansion alongside 26%+ adjusted EBITDA margins, reinforcing strong operating leverage despite US healthcare concentration.
📅 குறுகிய காலம்Earnings demonstrate resilience and dividend hike provides positive sentiment as the company enters its seasonally stronger H2 period.
📈 நீண்ட காலம்Ongoing M&A (CareSeed, Chirok Health) and AI-driven solutions are broadening service offerings beyond traditional payer administration into mid-market and clinical segments.
⚠ அபாய எச்சரிக்கைகள்
High client concentration: Top 3 clients contribute ~60.1% and Top 10 contribute 84.4% of revenues
Geographic concentration: Predominantly reliant on US healthcare regulatory dynamics
👀 கவனிக்க வேண்டியவை
Track execution into the seasonally strong H2 during the US Open Enrolment and Annual Enrolment Period (AEP), alongside the margin integration of Chirok Health.
Sagility Acquires US Healthcare Specialist Chirok Health to Expand Provider RCM Capabilities
Sagility Limited announced the acquisition of Chirok Health, a provider founded in 2020 specializing in Clinical Documentation Improvement (CDI), medical coding, coding QA, and revenue integrity. The acquisition bolsters Sagility's mid-revenue cycle management offerings alongside its recent CareSeed transaction. Deal consideration and financial terms were not disclosed in the press release. With Sagility's TTM revenue standing at Rs 7,617 Cr, the deal is aimed at accelerating cross-selling opportunities across its US healthcare payer and provider base.
நடுத்தரம் நம்பிக்கை
என்ன மாறியதுSagility has acquired Chirok Health, adding specialized clinical documentation improvement and medical coding capabilities to its services portfolio.
ஏன் இது முக்கியம்The deal strengthens Sagility's mid-revenue cycle offerings, helping broaden revenue beyond its top 10 clients (which contribute >90% of revenue) and enhancing provider-side services.
📅 குறுகிய காலம்Market focus will be on the undisclosed financial details of the deal, including acquisition cost and revenue contribution.
📈 நீண்ட காலம்Supports Sagility's strategic push into provider solutions and value-based care, complementing front- and back-end RCM while creating cross-sell avenues to its large payer client base.
⚠ அபாய எச்சரிக்கைகள்
Lack of disclosure on acquisition valuation, consideration, and target financial metrics.
Integration risks across clinical staffing and systems.
👀 கவனிக்க வேண்டியவை
Track subsequent statutory disclosures regarding acquisition cost, funding structure, and Chirok Health's annual revenue/margin profile to assess balance sheet impact and goodwill addition.
Sagility Q1 FY27: 27.6% Revenue Growth to ₹1,963.5 Cr; $35.3M New ACV Signed
Sagility reported a strong start to FY27 with Q1 revenue reaching ₹1,963.5 crore, a 27.6% YoY increase. Adjusted PAT grew 35.1% YoY to ₹269.7 crore, maintaining a healthy 24% EBITDA margin despite absorbing statutory wage hikes in Karnataka and Telangana. The company signed $35.3 million in new steady-state Annual Contract Value (ACV) and successfully integrated the CareSeed acquisition, adding 26 mid-market clients. Management is pivoting towards outcome-driven managed service deals and leveraging its 'Sagility Synchrony' AI platform to drive operational efficiencies.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has successfully integrated CareSeed to expand into the mid-market segment and is transitioning from fragmented process-led models to integrated, AI-led outcome-driven frameworks.
ஏன் இது முக்கியம்The ability to maintain 24% EBITDA margins while absorbing significant statutory wage hikes demonstrates strong operating leverage and pricing power in the specialized US healthcare BPM market.
📅 குறுகிய காலம்The stock may see positive sentiment following strong YoY growth and margin resilience despite seasonal sequential declines and wage pressures.
📈 நீண்ட காலம்Structural shift towards AI-led BPaaS and mid-market expansion via acquisitions could help diversify the high client concentration (Top 10 clients > 90% revenue).
⚠ அபாய எச்சரிக்கைகள்
High client concentration (Top 10 clients contribute >90% revenue)
US regulatory shifts impacting geographic concentration
Potential margin dilution from the new 3% ESOP pool
👀 கவனிக்க வேண்டியவை
Monitor the execution of the $35.3M new ACV and the impact of the proposed 3% ESOP pool on future employee costs. Watch for seasonal revenue spikes in Q3 and Q4, which typically align with the US healthcare open enrollment period.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
27.6% Revenue Growth in Q1 FY27; Sagility Acquires CareSeed to Expand Client Base to 109
Sagility reported a strong start to FY27 with Q1 revenue reaching ₹1,963.5 Cr, a 27.6% YoY increase (15.2% in constant currency). Adjusted PAT grew 35.1% YoY to ₹269.7 Cr, supported by resilient Adjusted EBITDA margins of 24.0%. A key strategic highlight was the acquisition of CareSeed, which added 26 new client groups and helped reduce top-10 client concentration from 90.5% in FY25 to 84.1%. The company also secured $35.3 million in steady-state Annual Contract Value (ACV) during the quarter.
உச்சம் நம்பிக்கை
என்ன மாறியதுSagility has successfully integrated the CareSeed acquisition and demonstrated strong organic growth while beginning to diversify its highly concentrated client base.
ஏன் இது முக்கியம்The reduction in top-10 client concentration from 90.5% to 84.1% is a critical de-risking step for a company where the top 3 clients still contribute 60.1% of revenue. Maintaining 24% EBITDA margins despite growth investments indicates strong operational efficiency.
📅 குறுகிய காலம்The stock may see positive sentiment due to strong YoY earnings growth and the successful addition of 27 new clients in a single quarter.
📈 நீண்ட காலம்Structural improvements in client diversification and expansion into Medicare Advantage analytics via CareSeed position the company for sustainable growth in the U.S. healthcare BPM market.
⚠ அபாய எச்சரிக்கைகள்
High client concentration (Top 3 clients still contribute 60.1% of revenue)
100% geographic concentration in the U.S. healthcare market
High voluntary attrition rate of 28.6%
👀 கவனிக்க வேண்டியவை
Monitor the integration of CareSeed and its impact on mid-market segment margins. Watch for the return of seasonal revenues in Q3 and Q4 FY27, which typically drive higher volumes in the U.S. healthcare payer market.
Sagility Q1 FY27: PAT Jumps 45.9% YoY to ₹216.8 Cr; Revenue Up 27.6%
Sagility Limited reported a strong start to FY27 with revenue from operations growing 27.6% YoY to ₹1,963.5 cr. Net profit (PAT) surged 45.9% YoY to ₹216.8 cr, driven by volume growth and the integration of the CareSeed acquisition. While EBITDA margins remained stable at 23.0%, the company successfully reduced its Top 3 client concentration to 60.1% from 66.2% in FY25. The total headcount expanded to 47,307, reflecting an 18.5% increase in delivery capacity to support business momentum.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has delivered strong double-digit growth in both revenue and profit while successfully diversifying its client base through acquisitions.
ஏன் இது முக்கியம்The results validate Sagility's ability to scale its specialized healthcare BPM model and reduce dependency on its largest clients, which was previously a significant risk factor.
📅 குறுகிய காலம்The stock is likely to react positively to the strong YoY growth in PAT and the successful reduction in client concentration.
📈 நீண்ட காலம்Structural improvements in client diversification and expansion into mid-market segments via M&A suggest a sustainable growth trajectory in the US healthcare market.
⚠ அபாய எச்சரிக்கைகள்
High geographic concentration (100% US-linked revenue)
High client concentration (Top 10 at 84.1%)
Voluntary attrition rate remains high at 28.6%
👀 கவனிக்க வேண்டியவை
Monitor the integration of CareSeed and the company's ability to maintain EBITDA margins near its 25% target. Watch for seasonal revenue peaks in Q3 and Q4 which typically drive higher profitability in the healthcare payer segment.
₹0.10 Final Dividend: Sagility Limited Sets Record Date and TDS Guidelines for FY2025-26
Sagility Limited has announced a final dividend of ₹0.10 per equity share for the financial year 2025-26. The record date to determine shareholder eligibility is fixed for August 7, 2026, with the payout subject to approval at the AGM on August 20, 2026. The company has detailed Tax Deduction at Source (TDS) procedures, including a 10% rate for resident shareholders with valid PAN and a ₹10,000 exemption threshold for individuals. Shareholders must submit tax-related documents by August 14, 2026, to avail of lower or nil withholding rates.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has established the specific timeline and tax compliance requirements for its previously recommended final dividend for FY26.
ஏன் இது முக்கியம்This is a routine administrative update that clarifies the net payout shareholders will receive after tax and the deadlines for submitting exemption forms.
Dividend per share: ₹0.10ரெக்கார்ட் தேதி: ஆகஸ்ட் 7, 2026AGM Date: ஆகஸ்ட் 20, 2026TDS Rate (Resident with PAN): 10%Dividend Yield (at ₹41.2): 0.24%
📅 குறுகிய காலம்The stock may see minor price adjustments around the ex-dividend date; however, the small dividend amount (0.24% yield) is unlikely to cause significant volatility.
📈 நீண்ட காலம்Limited structural significance as this is a routine distribution of profits representing a small portion of TTM PAT.
👀 கவனிக்க வேண்டியவை
Shareholders should ensure their PAN and Aadhaar are linked and bank account details are updated with their Depository Participant before the August 7 record date.
₹149.50 Cr Partial Redemption of Unlisted NCDs to Sagility B.V.
Sagility Limited has completed a partial redemption of 1,495 unsecured, unlisted Non-Convertible Debentures (NCDs) on July 03, 2026. The total principal amount paid was ₹149.50 Cr to the debenture holder, Sagility B.V., based on a 2021 trust deed. Additionally, the company paid ₹2.88 Cr in interest for the period April-July 2026 at an 8% annual rate. This redemption represents approximately 19% of the company's total reported debt of ₹787 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has partially repaid its unsecured, unlisted debt, reducing its total debt obligations by ₹149.50 Cr.
ஏன் இது முக்கியம்This move reduces the company's interest burden and further strengthens an already healthy balance sheet (D/E ratio was 0.08). It demonstrates the company's ability to utilize cash flows for de-leveraging.
Redemption Amount: ₹149.50 கோடிInterest Paid: ₹2.88 கோடிInterest Rate: ஆண்டுக்கு 8%Redemption vs Total Debt: ~19%Redemption vs Net Worth: ~1.4%
📅 குறுகிய காலம்The announcement is likely to be viewed neutrally to slightly positively by the market as it confirms scheduled debt servicing and reduction.
📈 நீண்ட காலம்Consistent debt reduction improves financial flexibility for Sagility's stated strategy of M&A and expansion into the US healthcare mid-market.
⚠ அபாய எச்சரிக்கைகள்
Related-party transaction (payment to Sagility B.V.)
👀 கவனிக்க வேண்டியவை
Investors should monitor the reduction in interest costs in the next quarterly P&L and track if further redemptions are planned for the remaining unlisted debt.
Sagility Limited has issued a clarification regarding its proposed Employee Stock Options and Performance Stock Units Scheme 2026. The company emphasized that at least 70% of performance criteria for senior management will be tied to core financial parameters like revenue and margins, while the remaining 30% will focus on operational metrics. It further clarified that the 1% maximum grant per employee is a regulatory ceiling, not an intended allocation, and that CEO remuneration remains capped at 5% of net profits. The scheme follows a 'pay-at-risk' structure with a vesting period of 1-3 years and an exercise period of up to 2 years.
முக்கிய அம்சங்கள்
At least 70% of performance-linked criteria for senior management will be based on core financial parameters like revenue, margin, and return ratios.The 1% maximum grant per employee is a regulatory ceiling and not the intended allocation for any individual.CEO remuneration is strictly restricted to 5% of net profits as per the provisions of the Companies Act.The exercise period for vested options/PSUs is set at up to 2 years from the date of vesting.Vesting of Performance Stock Units (PSUs) is contingent upon achieving mandatory, pre-defined performance criteria over 1-3 years.
👀 கவனிக்க வேண்டியவை
Investors should note the company's commitment to performance-linked dilution and governance controls. This clarification reduces concerns regarding excessive management payouts and aligns employee incentives with long-term shareholder value.
Sagility Clarifies ESOP & PSU Scheme 2026; Sets 3-Year Max Vesting Period
Sagility Limited has issued additional clarifications regarding its 'Employee Stock Options and Performance Stock Units Scheme 2026'. The scheme features a maximum vesting period of 3 years and links PSU vesting to mandatory performance criteria, including consolidated revenue and EBITDA margins. The company emphasized a 'pay-at-risk' incentive model to align employee rewards with shareholder interests. Costs for grants to subsidiary employees will be borne by the respective subsidiary entities, ensuring no undue burden on the parent company.
முக்கிய அம்சங்கள்
Maximum vesting period for the ESOS 2026 scheme is fixed at 3 years from the date of grant.PSU vesting is contingent on achieving pre-defined targets for Consolidated Revenue and EBITDA/Adjusted EBITDA margins.The scheme extends to subsidiary employees, with costs specifically borne by those respective subsidiary entities.Company commits to annual disclosures of aggregate grant data, weighted-average exercise prices, and realized vesting outcomes.The scheme will be administered through the 'Sagility ESOP Trust' in compliance with Section 67 of the Companies Act, 2013.
👀 கவனிக்க வேண்டியவை
Investors should view the performance-linked nature of the PSUs as a positive governance measure that protects against dilution without merit. Monitor future annual reports for the actual dilution impact and the specific performance targets achieved.
Sagility Acquires CareSeed to Boost AI-led Healthcare Quality Ops; Target CY25 Revenue at $5.1M
Sagility Limited has completed the 100% acquisition of CareSeed, a U.S.-based healthcare analytics firm specializing in HEDIS quality reporting and Medicare Advantage. CareSeed reported CY25 revenues of $5.1 million with a robust EBITDA margin of 31.4% ($1.6 million). The acquisition is expected to be immediately EPS accretive and adds 28 new health plan clients to Sagility's portfolio. This strategic move integrates CareSeed's cloud-native platforms, Forecast and Harvest, to accelerate Sagility's AI-led quality orchestration capabilities.
முக்கிய அம்சங்கள்
100% acquisition of CareSeed to strengthen position in the U.S. Medicare Advantage market.CareSeed delivered $5.1 million in revenue and $1.6 million in EBITDA (31.4% margin) in CY25.Adds 28 new small and mid-sized U.S. payer clients, creating immediate cross-sell opportunities.The transaction is EPS accretive and closed on June 11, 2026.Integrates NCQA-certified platforms Forecast and Harvest for AI-led healthcare quality operations.
👀 கவனிக்க வேண்டியவை
Investors should view this acquisition positively as it adds high-margin, recurring revenue and expands Sagility's footprint in the lucrative U.S. healthcare analytics space. Monitor the company's ability to cross-sell its broader clinical services to CareSeed's existing client base.
Sagility Limited to acquire US-based CareSeed LLC for up to US$ 30 Million
Sagility Limited, through its step-down subsidiary Sagility LLC, has entered into a definitive agreement to acquire 100% of CareSeed LLC, a US-based healthcare analytics firm. The total consideration is valued at up to US$ 30 million, comprising an upfront cash payment of US$ 17.5 million and performance-linked earn-outs of up to US$ 12.5 million. CareSeed reported a turnover of US$ 5.1 million in CY2025 and provides specialized NCQA-certified HEDIS reporting and risk adjustment solutions. This acquisition is intended to strengthen Sagility's technology-led healthcare offerings and expand its footprint in the US payer ecosystem.
முக்கிய அம்சங்கள்
Acquisition of 100% stake in CareSeed LLC for a total consideration of up to US$ 30 million.Deal structure includes US$ 17.5 million upfront and up to US$ 12.5 million in contingent payments based on revenue growth synergies.CareSeed's revenue has grown consistently from US$ 3.6 million in CY2023 to US$ 5.1 million in CY2025.Strategic expansion into NCQA-certified HEDIS reporting and STAR performance management for mid-sized U.S. health plans.The acquisition was completed on June 11, 2026, through a cash consideration.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive strategic expansion that enhances Sagility's high-margin technology capabilities in the US healthcare market. Monitor the successful integration of CareSeed's platform and the achievement of the projected revenue synergies.
Sagility Limited has issued a postal ballot notice to seek shareholder approval for its new 'Employee Stock Options and Performance Stock Units Scheme 2026'. The scheme involves granting up to 3.09 crore options and 12.36 crore performance stock units (PSUs), totaling 15.45 crore equity shares. The initiative aims to incentivize employees across the company and its subsidiaries through a dedicated Sagility ESOP Trust. E-voting for these resolutions is scheduled to take place from May 30 to June 28, 2026.
முக்கிய அம்சங்கள்
Proposed ESOS 2026 includes 3,09,10,845 options and 12,36,43,222 performance stock units (PSUs).Total shares exercisable under the scheme amount to 15,45,54,067 equity shares of face value Rs. 10 each.The scheme will be implemented through the 'Sagility ESOP Trust' which may involve secondary market purchases.E-voting period is set for May 30, 2026, to June 28, 2026, with results expected by June 30, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the potential equity dilution that may arise from the exercise of 15.45 crore shares. Evaluate whether the performance-linked nature of the PSUs sufficiently aligns management incentives with long-term shareholder value.
Sagility Limited Tax Demand Reduced to Rs 56.68 Crore via Rectification Order
Sagility Limited has received a rectification order from the Income Tax Department for Assessment Year 2023-24, which significantly reduces a previously issued tax demand. The total demand, including interest, has been revised downward from Rs 100.00 crore to Rs 56.68 crore. This demand is primarily based on transfer pricing adjustments amounting to Rs 189.50 crore. The company has already filed an appeal against this order and maintains that the demand is not maintainable.
முக்கிய அம்சங்கள்
Income tax demand revised from Rs 100.00 crore to Rs 56.68 crore including interestDemand pertains to Assessment Year 2023-24 following transfer pricing adjustments of Rs 189.50 croreCompany filed an appeal before the Commissioner of Income Tax (Appeals) on May 12, 2026Management states the rectified order has no material impact on current financials or operations
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the tax appeal as the demand represents a significant potential liability, although the reduction provides some relief.
Sagility Ltd Reports Strong FY26 Performance with 29.1% Revenue Growth and 39.5% PAT Surge
Sagility Limited delivered a robust FY26 performance, with annual revenue reaching ₹71,929 million, a 29.1% year-on-year increase. The company's adjusted PAT grew significantly by 39.5% to ₹11,306 million, supported by strong execution and the BroadPath acquisition. Management highlighted a reduction in top-client concentration, with the top 3 clients now accounting for less than 60% of revenue. A final dividend of ₹0.10 per share has been recommended, reflecting healthy cash flow conversion of 104.6%.
முக்கிய அம்சங்கள்
FY26 Revenue grew 29.1% YoY to ₹71,929 million, with organic constant currency growth at 15%Adjusted PAT for the full year surged 39.5% to ₹11,306 million with a margin of 15.7%Client diversification improved as the number of $20M+ accounts increased from 4 in FY23 to 9 in FY26The board recommended a final dividend of ₹0.10 per share following strong operating cash flowQ4 adjusted EBITDA margin stood at 24.9%, despite the full-year impact of the BroadPath acquisition
👀 கவனிக்க வேண்டியவை
Investors should note the strong organic growth and successful integration of BroadPath as indicators of scalability. The improving client concentration and favorable Medicare Advantage rate updates suggest a stable outlook for FY27.
Sagility Limited Recommends Final Dividend of Rs. 0.10 Per Share for FY 2025-26
The Board of Directors of Sagility Limited has recommended a final dividend of Rs. 0.10 per equity share for the financial year ended March 31, 2026. This dividend is calculated on a face value of Rs. 10 per share, representing a 1% payout on the nominal value. The proposal is currently subject to the approval of shareholders at the upcoming Annual General Meeting (AGM). The company will announce the specific record date and payment schedule at a later date.
முக்கிய அம்சங்கள்
Recommended final dividend of Rs. 0.10 per equity share for FY 2025-26Dividend rate is 1% based on the face value of Rs. 10 per shareApproval pending from shareholders at the ensuing Annual General MeetingRecord date and payment date to be notified in due course
👀 கவனிக்க வேண்டியவை
Investors should track the upcoming AGM and record date announcements to ensure eligibility for the dividend payout. The modest dividend reflects a start to shareholder returns following the fiscal year-end.
Sagility Limited's Board has approved the 'Employee Stock Options and Performance Stock Units Scheme 2026', which is now subject to shareholder approval via postal ballot. The scheme creates a pool of 15.45 crore equity shares, representing approximately 3.30% of the company's current paid-up capital. The pool is divided into 3.09 crore stock options and 12.36 crore Performance Stock Units (PSUs). While options will be priced at or above market price, PSUs will be issued at the face value of Rs. 10 per share, aimed at retaining key talent.
முக்கிய அம்சங்கள்
Total pool of 15,45,54,067 equity shares representing 3.30% of current paid-up capital.Scheme includes 3,09,10,845 Options and 12,36,43,222 Performance Stock Units (PSUs).Exercise price for PSUs set at the face value of Rs. 10 per share.Exercise price for Options will be at or above the market price on the grant date.Maximum exercise period of 2 years from the date of each vesting.
👀 கவனிக்க வேண்டியவை
Investors should account for a potential 3.3% equity dilution in their long-term valuation models. Monitor the specific performance hurdles for PSUs when disclosed to ensure management incentives align with shareholder returns.
Sagility Ltd Recommends ₹0.10 Dividend and Approves New ESOS Scheme for FY26
Sagility Limited has announced its audited financial results for the fiscal year ended March 31, 2026, alongside a dividend recommendation. The Board proposed a final dividend of ₹0.10 per equity share (1% of face value) and approved a new Employee Stock Option Scheme (ESOS 2026). The auditors provided a clean, unmodified opinion on the consolidated financial statements, ensuring reporting reliability. Shareholders will need to approve both the dividend and the ESOS through the upcoming AGM and postal ballot.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹0.10 per equity share of ₹10 each for FY26.Approved 'ESOS 2026' for granting stock options and performance units to employees and directors.Statutory auditors B S R & Co. LLP issued an unmodified audit report for the consolidated results.The Board meeting concluded on May 12, 2026, after approving standalone and consolidated results.
👀 கவனிக்க வேண்டியவை
Investors should review the detailed profit and loss figures in the full report to assess growth trajectory. The nominal dividend suggests a focus on capital reinvestment or conservative payouts.
Sagility FY26 Revenue Jumps 29.1% to ₹71,929M; Adjusted PAT Surges 39.5%
Sagility Limited reported a robust financial performance for FY26, with consolidated revenue growing 29.1% YoY to ₹71,929 million. Adjusted PAT witnessed a significant surge of 39.5% to ₹11,306 million, while Adjusted EBITDA margins remained stable at 25.1%. The company demonstrated successful client diversification, reducing the revenue contribution of its top 5 clients from 77.9% to 70.4%. A final dividend of ₹0.10 per share was also announced, reflecting a strong cash position.
முக்கிய அம்சங்கள்
FY26 Revenue reached ₹71,929 million, up 29.1% YoY (23.6% in constant currency terms).Adjusted PAT for the full year rose 39.5% YoY to ₹11,306 million with a 15.7% margin.Added 17 new clients in FY26, expanding the total active client groups to 82.Revenue concentration from top 10 clients improved significantly to 83.9% from 90.5% in FY25.Board recommended a final dividend of ₹0.10 per share for the fiscal year ended March 31, 2026.
👀 கவனிக்க வேண்டியவை
The strong double-digit growth and improving client diversification profile strengthen the long-term investment case for Sagility. Investors should monitor the impact of AI integration on margins and keep an eye on voluntary attrition which rose to 29.4%.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
